HCWB

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.

Wall Street analysts forecast HCWB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCWB is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

HCW Biologics Inc revenue for the last quarter amounts to 15.61K USD, decreased -96.34 % YoY.

HCW Biologics Inc. EPS for the last quarter amounts to -2.02 USD, decreased -51.09 % YoY.

HCW Biologics Inc (HCWB) has 36 emplpoyees as of December 15 2025.

Today HCWB has the market capitalization of 4.89M USD.